A Synthetic Bottle-brush Polyelectrolyte Reduces Friction and Wear of Intact and Previously Worn Cartilage
- PMID: 31608307
- PMCID: PMC6788642
- DOI: 10.1021/acsbiomaterials.9b00085
A Synthetic Bottle-brush Polyelectrolyte Reduces Friction and Wear of Intact and Previously Worn Cartilage
Abstract
A poly(7-oxanorbornene-2-carboxylate) polymer containing pendent triethyleneglycol (TEG) chains of 2.8 MDa ("2.8M TEG") was synthesized and evaluated for long-term lubrication and wear reduction of ex vivo bovine cartilage as well as for synovitis in rats and dogs after intra-articular administration. Bovine cartilage surfaces were tested under torsional friction for 10,080 rotations while immersed in either saline, bovine synovial fluid (BSF), or 2.8M TEG. For each solution, coefficient of friction (μ), changes in surface roughness, and lost cartilage glycosaminoglycan were compared. To directly compare 2.8M TEG and BSF, additional samples were tested sequentially in BSF, BSF, 2.8M TEG, and then BSF. Finally, another set of samples were tested twice in saline to induce surface roughness and then tested in BSF, Synvisc, or 2.8M TEG to determine each treatment's effect on worn cartilage. Next, male Lewis rats were injected in one knee with 2.8M TEG or saline and evaluated for effects on gait, and female beagles were injected with either 2.8M TEG or saline in one knee, and their synovial tissues analyzed for inflammation by H&E staining. Treatment with 2.8M TEG lowers μ, lessens surface roughness, and minimizes glycosaminoglycan loss compared to saline. The 2.8M TEG also reduces μ compared to BSF in pairwise testing and on worn cartilage surfaces. Injection of 2.8M TEG in rat or beagle knees gives comparable effects to treatment with saline, and does not cause significant synovitis.
Keywords: CT imaging; biolubricant; chondroprotection; osteoarthritis; synovial fluid; viscosupplement.
Conflict of interest statement
COMPETING INTERESTS M.W.G., M.W., and B.D.S. had a conflict of interest, as they owned shares in FlexBiomedical, Inc, a company that specializes in the design and development of biolubricants for OA treatment, as well as have grant funding from the NIH and Coulter Foundation.
Figures







References
-
- Felson DT; Lawrence RC; Dieppe PA; Hirsch R; Helmick CG; Jordan JM; Kington RS; Lane NE; Nevitt MC; Zhang Y; Sowers M; McAlindon T; Spector TD; Poole AR; Yanovski SZ; Ateshian G; Sharma L; Buckwalter JA; Brandt KD; Fries JF, Osteoarthritis: new insights. Part 1: the disease and its risk factors. Annals of Internal Medicine 2000, 133 (8), 635–46. - PubMed
-
- Buckwalter JA; Mankin HJ, Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation. Instructional Course Lectures 1998, 47, 487–504. - PubMed
-
- Silvast TS; Kokkonen HT; Jurvelin JS; Quinn TM; Nieminen MT; Toyras J, Diffusion and near-equilibrium distribution of MRI and CT contrast agents in articular cartilage. Physics in Medicine and Biology 2009, 54, 6823–36. - PubMed
-
- Ludwig TE; McAllister JR; Lun V; Wiley JP; Schmidt TA, Diminished cartilage-lubricating ability of human osteoarthritic synovial fluid deficient in proteoglycan 4: Restoration through proteoglycan 4 supplementation. Arthritis and Rheumatism 2012, 64 (12), 3963–71. - PubMed
-
- Schmidt TA; Gastelum NS; Nguyen QT; Schumacher BL; Sah RL, Boundary lubrication of articular cartilage: role of synovial fluid constituents. Arthritis and Rheumatism 2007, 56 (3), 882–891. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials